IMMUNIC INC (IMUX) Stock Price, Forecast & Analysis
NASDAQ:IMUX • US4525EP1011
IMUX Key Statistics, Chart & Performance
The current stock price of IMUX is 0.9125 USD. In the past month the price increased by 42.82%. In the past year, price decreased by -8.75%.
IMUX Technical Analysis
ChartMill assigns a technical rating of 7 / 10 to IMUX. When comparing the yearly performance of all stocks, IMUX turns out to be only a medium performer in the overall market: it outperformed 52.68% of all stocks.
IMUX Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to IMUX. While IMUX seems to be doing ok healthwise, there are quite some concerns on its profitability.
IMUX Financial Highlights
Over the last trailing twelve months IMUX reported a non-GAAP Earnings per Share(EPS) of -0.83. The EPS increased by 32.52% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -253.16% | ||
| ROE | -981.49% | ||
| Debt/Equity | 0 |
IMUX Forecast & Estimates
15 analysts have analysed IMUX and the average price target is 5.48 USD. This implies a price increase of 500.82% is expected in the next year compared to the current price of 0.9125.
IMUX Ownership
IMUX Latest News, Press Relases and Analysis
IMUX Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 15.94 | 409.148B | ||
| AMGN | AMGEN INC | 16.38 | 198.801B | ||
| GILD | GILEAD SCIENCES INC | 17.38 | 192.281B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.11 | 124.696B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.29 | 84.911B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 46.93 | 41.535B | ||
| INSM | INSMED INC | N/A | 31.724B | ||
| BIIB | BIOGEN INC | 12.92 | 28.841B | ||
| NTRA | NATERA INC | N/A | 28.695B | ||
| UTHR | UNITED THERAPEUTICS CORP | 16.07 | 20.396B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About IMUX
Company Profile
Immunic, Inc. is a clinical-stage biopharmaceutical company, which develops a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases. The company is headquartered in New York City, New York and currently employs 91 full-time employees. The company went IPO on 2014-04-17. The firm is engaged in pursuing clinical development of programs, which include the vidofludimus calcium (IMU-838) program, which is in Phase III clinical development for patients with relapsing multiple sclerosis (RMS), and which has shown therapeutic activity in Phase II clinical trials in patients suffering from relapsing-remitting MS, progressive MS and moderate-to-severe ulcerative colitis; the IMU-856 program, which is targeted to regenerate bowel epithelium and restore intestinal barrier function, which could potentially be applicable in numerous gastrointestinal diseases, such as celiac disease, inflammatory bowel disease, Graft-versus-Host-Disease and weight management, and the IMU-381 program, which is a molecule being developed to specifically address the needs of gastrointestinal diseases.
Company Info
IMMUNIC INC
1200 Avenue Of The Americas, Suite 200
New York City NEW YORK 10036 US
CEO: Daniel Vitt
Employees: 91
Phone: 13322559818
IMMUNIC INC / IMUX FAQ
Can you describe the business of IMMUNIC INC?
Immunic, Inc. is a clinical-stage biopharmaceutical company, which develops a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases. The company is headquartered in New York City, New York and currently employs 91 full-time employees. The company went IPO on 2014-04-17. The firm is engaged in pursuing clinical development of programs, which include the vidofludimus calcium (IMU-838) program, which is in Phase III clinical development for patients with relapsing multiple sclerosis (RMS), and which has shown therapeutic activity in Phase II clinical trials in patients suffering from relapsing-remitting MS, progressive MS and moderate-to-severe ulcerative colitis; the IMU-856 program, which is targeted to regenerate bowel epithelium and restore intestinal barrier function, which could potentially be applicable in numerous gastrointestinal diseases, such as celiac disease, inflammatory bowel disease, Graft-versus-Host-Disease and weight management, and the IMU-381 program, which is a molecule being developed to specifically address the needs of gastrointestinal diseases.
Can you provide the latest stock price for IMMUNIC INC?
The current stock price of IMUX is 0.9125 USD. The price increased by 4.87% in the last trading session.
What is the dividend status of IMMUNIC INC?
IMUX does not pay a dividend.
What is the ChartMill rating of IMMUNIC INC stock?
IMUX has a ChartMill Technical rating of 7 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What is the analyst forecast for IMUX stock?
15 analysts have analysed IMUX and the average price target is 5.48 USD. This implies a price increase of 500.82% is expected in the next year compared to the current price of 0.9125.
Would investing in IMMUNIC INC be a good decision?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on IMUX.
Can you provide the upcoming earnings date for IMMUNIC INC?
IMMUNIC INC (IMUX) will report earnings on 2026-02-19, after the market close.